Clinical Trial

CHinese ischEmic Stroke Beyond 4.5 Hours With TeNecteplase Under Optimized Non-Contrast CT Selection

Study acronym: CHESTNUT
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The CHESTNUT trial is a multicenter, open-label, blinded-endpoint, randomized, controlled, phase 3 trial. The primary objective of this study is to explore the efficacy and safety of the dose of 0.25 mg/kg tenecteplase (TNK) in Chinese acute ischemic stroke (AIS) patients without substantial infarction on non-contrast computed tomography (NCCT) in an extended time window.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-20; most recent amendment 2025-12-22.
Status change: Not Yet Recruiting → Recruiting 2025-12-22
Trial Details
NCT Number NCT06994975
Lead Sponsor Huashan Hospital
Conditions Acute Ischemic Stroke
Enrollment 890 participants
Start Date 2025-11-03
Primary Completion 2028-03 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-30